Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,230.71
(
-0.16%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
78,037.36
(
0.53%
)
News Focus
News Focus
Post# of 257443
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122886
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iandy post# 157363

Monday, 02/25/2013 12:57:19 PM

Monday, February 25, 2013 12:57:19 PM

Post# of 257443

ELN—All that is lacking is another suitor and an objective sum of the parts analysis.

Pharma companies per se do not generally acquire firms for their royalty streams. Thus, a better offer would have to come from a firm similar to Royalty Pharma. Possible, but not likely, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today